アルベンダゾール駆虫薬の世界市場-2022-2029

市場力学

蠕虫症の治療におけるアルベンダゾール駆虫薬の需要拡大

蠕虫（ぜんちゅう）症は、蠕虫（ぜんちゅう）と呼ばれる寄生虫が体の大部分に寄生する、ヒトやその他の動物の大寄生虫症として知られています。有病率の上昇は、回虫、鉤虫、鞭虫などによる駆虫薬市場を牽引すると予想されます。それと引き換えに、世界経済の規模が改善されると予測されています。WHOによると、2020年3月時点で、世界で15億人近くが土壌を媒介とする蠕虫の感染症に苦しんでいます。全世界の人間人口の24％がこの数字を占めています。アスカリス・ルンブリコイデス（回虫）、トリチュラ（鞭虫）、ネカトール・アメリカヌス、アンシロストマ・デュオデナーレなどが、疾病負担を高める主要種（鉤虫）です。WHO情報によると、2020年3月にサハラ以南のアフリカ、南北アメリカ、中国、アジアの国々で土壌伝染性蠕虫の感染分布が高くなっています。例えば「全国虫下しの日」は、インド政府保健家族福祉省が虫のいない国にするために大きな取り組みを行っています。WHOによると、インドでは1歳から14歳までの2億4100万人の子どもたちが寄生虫である腸内寄生虫のリスクが高いとされています。また、政府は啓蒙活動や蠕虫感染症の撲滅に向けた提言の策定も期待されています。

一方、アルベンダゾール駆虫薬の副作用である頭痛、首のこわばり、光に対する感受性の増加、錯乱、発熱などが市場シェアの抑制要因として作用する可能性があります。さらに、アルベンダゾールは出血や感染症のリスクを高める可能性があります。

世界のアルベンダゾール駆虫薬市場レポートでは、約51の市場データ表、45の図、190ページへのアクセスを提供するであろう

目次

第1章 調査手法と範囲

• 調査手法
• 市場の範囲

第2章 主な動向と発展

第3章 エグゼクティブサマリー

• タイプ別市場内訳
• アプリケーション別市場内訳
• 地域別市場内訳

第4章 市場の力学

• 市場影響要因
  • 促進要因
  • 抑制要因
  • ビジネスチャンス
• 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• PEST分析
• プライシング分析
• リインバースメント分析
• 法規制分析
• アンメットニーズ
• 特許動向

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、あるいは将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的取り組み

第7章 タイプ別

• 錠剤
• カプセル剤
• その他

第8章 エンドユーザー別

• ヒト
• 動物用医薬品

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他の欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第10章 競合情勢

• 競合シナリオ
• 競合他社の戦略分析
• 市況/シェア分析
• M&A（合併・買収）分析

第11章 企業プロファイル

• GlaxoSmithKline
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Fredun Pharmaceuticals Ltd
• Sequent Scientific
• Huazhong Pharmaceutical
• Zhongjia Pharmaceutical
• Jiangsu Qihui
• Salius Pharma
• Lasa Supergenerics Limited
• K.A. Malle Pharmaceuticals
• Supharma Chem

第12章 DataM

Market Overview

Albendazole anthelmintic drug market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 6.5% during the forecast period (2022-2029).

Albendazole, also known as albendazole, is an anthelmintic drug. It inhibits the production or replication of new insect larvae (worms) in the body. It is used to combat inflammatory diseases from worms like pork wire and dog tapestry. For various purposes, albendazole can be used in humans and livestock. The capillary disease is caused by Capillary pelican (dogs and cats), and C is used in poultry. Cati Felis (cats). Capillary bladders infect, so they are sometimes referred to as bladder worms. With albendazole. Due to growing neurocysticercosis cases, the demand for albendazole drugs will expand dramatically in the coming years (infection caused by the pork tapeworm in the muscles, brain, and eyes that may cause seizures, brain swelling, and vision problems).

Market Dynamics: Growing demand Albendazole Anthelmintic Drug in the treatment of Helmonthasis

Helmonthasis, also known as worm infection, is a human and other animal macroparasite disease that includes parasite worms in most of the body, known as helminths (helminths). A rise in the prevalence is expected to drive the market for anthelmintic medicine caused by roundworm, hookworm, whipworm and other worms. In exchange, the size of the global economy is projected to improve. According to the WHO, nearly 1.5 billion people worldwide have suffered from soil-borne helminth infection as of March 2020. 24 per cent of the global human population accounts for this figure. Ascaris lumbricoides (roundworms), trichuriasis trichiura (whipworms), necator americanus, and ancylostoma duodenale are major species that raise the disease burden (hookworms). According to WHO info, soil-transmitted helminth infection distribution in Sub-Saharan Africa, the Americas, China and countries in Asia was higher in March 2020. The National Deworming Day, for example, is a big effort by the Government of India's Ministry of Health and Family Welfare to make the nation worm-free. In India, 241 million children aged 1 to 14 years are at higher risk of parasitic intestinal worms, according to the WHO. The government is also expected to establish recommendations for awareness-raising and the eradication of helminth infection.

On the other hand, albendazole anthelmintic drug's side effects, such as headache, neck stiffness, increased sensitivity to light, confusion, and fever, may act as restraint of the market share. Further, Albendazole can increase your risk of bleeding or infection.

Market Segmentation: The tablet albendazole anthelmintic drug segment is projected to be the market's dominant segment during the forecast period

The tablets segment accounts for the largest market share of the global Albendazole Anthelmintic Drug market and is projected to rise during the forecast period at its highest CAGR. The category of tablets and powders is growing primarily because of ease of use and relatively better absorption

Different prevention steps for the management of parasites in animals are being introduced. Veterinarians rely on anthelmintic drugs to protect the animals' health as vaccines are not readily available, and better vaccines have to be developed. Companies take advantage of value capturing opportunities for improved animal health through increased available macrocyclic benzimidazoles and tetrahydro pyrimidines on the anthelmintic drugs market.

Geographical Penetration: North America is the dominating region during the forecast period

In North America, major research and development players will account for the significant share of global albendazole demand for medicines. The USA, for example. The Food and Drug Administration authorized the Cipla Abbreviated New Medication Request for Albendazole Tablets. Further, major players in the region are adopting the product launch to increase the product portfolio and gain competitive market share. Moreover, the demand for albendazole drugs in Asia-Pacific is expected to develop rapidly in the timeframe predicted, as the prevalence of helminthic infection is growing and increasing.

Competitive Landscape:

The albendazole anthelmintic drug market is moderately competitive, owing to major market players in the key regions such as the US, China, India and others. The key albendazole anthelmintic drug players contributing to the growth of the global market include GlaxoSmithKline, Fredun Pharmaceuticals Ltd, Sequent Scientific, Huazhong Pharmaceutical, Zhongjia Pharmaceutical, Jiangsu Qihui, Salius Pharma, Lasa Supergenerics Limited, K.A. Malle Pharmaceuticals, Supharma Chem, among others. The major players are adopting new product launch and expansion strategies for global growth in the albendazole anthelmintic drug market. In June 2020, Pharma major Lupin announced that it has received approval for its Albendazole Tablets USP, 200 mg, from the U.S. FDA, to market a generic equivalent of Albenza Tablets, 200 mg, of Impax Laboratories Inc. In April 2021, Dr. Reddy's Laboratories along with its subsidiaries announced the launch of Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, approved by the U.S. Food and Drug Administration (USFDA).

COVID-19 Impact: Positive impact on the global Albendazol Anthelmintic Drug market

With the continuing breakout of coronavirus COVID-19, the unprecedented need for medications to tackle the novel infection has been intensified. As a result, AI, Gero, is recognized as a global expert in AI-driven drug developments and validating promising anthelmintic drug therapy potentials for COVID-19. As a result, the treatment of coronavirus in patients with niclosamide has proven to be successful. It has been approved in the U.S., Italy, France, and a few other countries where active COVID-19 patients are high. With the authorization of niclosamide, the effective use of AI-driven drug development approaches to build upon revenue-generating opportunities in industries on the anthelmintics market increases. Anthelmintic drug market firms are working to carry out clinical trials of existing therapeutic drugs that can be effective for treating coronavirus, which has further led to the demand for albendazole anthelmintic drug.

The global albendazole anthelmintic drug market report would provide an access to approximately 51 market data tables, 45 figures and 190 pages

Table of Contents

Scope and Methodology

• 1.1. Research Methodology
• 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

• 3.1. Market Snippet by Type
• 3.2. Market Snippet by Application
• 3.3. Market Snippet by Region

4. Market Dynamics

• 4.1. Market impacting factors
  • 4.1.1. Drivers
  • 4.1.2. Restraints
  • 4.1.3. Opportunities
• 4.2. Impact analysis

5. Industry Analysis

• 5.1. Porter's five forces analysis
• 5.2. Supply Chain analysis
• 5.3. PEST Analysis
• 5.4. Pricing Analysis
• 5.5. Reimbursement Analysis
• 5.6. Regulatory Analysis
• 5.7. Unmet Needs
• 5.8. Patent Trends

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives

7. By Type

• 7.1. Introduction
  • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Type Segment
  • 7.1.2. Market attractiveness index, By Type Segment
• 7.2. Tablet*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
• 7.3. Capsule
• 7.4. Others

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Application Segment
  • 8.1.2. Market attractiveness index, By Application Segment
• 8.2. Human*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
• 8.3. Veterinary

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key region-specific dynamics
  • 9.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. South America
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
  • 9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 9.3.5.1. Brazil
    • 9.3.5.2. Argentina
    • 9.3.5.3. Rest of South America
• 9.4. Europe
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
  • 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 9.4.5.1. Germany
    • 9.4.5.2. U.K.
    • 9.4.5.3. France
    • 9.4.5.4. Spain
    • 9.4.5.5. Italy
    • 9.4.5.6. Rest of Europe
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
  • 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

10. Competitive Landscape

• 10.1. Competitive scenario
• 10.2. Competitor strategy analysis
• 10.3. Market positioning/share analysis
• 10.4. Mergers and acquisitions analysis

11. Company Profiles

• 11.1. GlaxoSmithKline*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Fredun Pharmaceuticals Ltd
• 11.3. Sequent Scientific
• 11.4. Huazhong Pharmaceutical
• 11.5. Zhongjia Pharmaceutical
• 11.6. Jiangsu Qihui
• 11.7. Salius Pharma
• 11.8. Lasa Supergenerics Limited
• 11.9. K.A. Malle Pharmaceuticals
• 11.10. Supharma Chem
• List not Exhaustive*

12. DataM

• 12.1. Appendix
• 12.2. About us and services
• 12.3. Contact us